INBX Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -2204.15% compared to Inhibrx Biosciences, Inc.'s net margin of -116.82%. Inhibrx Biosciences, Inc.'s return on equity of -151.49% beat Agenus, Inc.'s return on equity of --.

Inhibrx Biosciences, Inc. has a consensus price target of $12.00, signalling downside risk potential of -86.07%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 258.53%. Given that Agenus, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Agenus, Inc. is more attractive than Inhibrx Biosciences, Inc..

Inhibrx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.

Inhibrx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Inhibrx Biosciences, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Inhibrx Biosciences, Inc.'s net income of -$35.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Inhibrx Biosciences, Inc.'s price-to-earnings ratio is 0.20x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences, Inc. is 936.51x versus 0.87x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of -2204.15% compared to Inhibrx Biosciences, Inc.'s net margin of -2301.55%. Inhibrx Biosciences, Inc.'s return on equity of -151.49% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Inhibrx Biosciences, Inc. has a consensus price target of $12.00, signalling downside risk potential of -86.07%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 46.1%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Inhibrx Biosciences, Inc..

Inhibrx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Inhibrx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Inhibrx Biosciences, Inc. quarterly revenues are --, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Inhibrx Biosciences, Inc.'s net income of -$35.3M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Inhibrx Biosciences, Inc.'s price-to-earnings ratio is 0.20x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences, Inc. is 936.51x versus 51.10x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals, Inc. has a net margin of -2204.15% compared to Inhibrx Biosciences, Inc.'s net margin of 10.18%. Inhibrx Biosciences, Inc.'s return on equity of -151.49% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.

Inhibrx Biosciences, Inc. has a consensus price target of $12.00, signalling downside risk potential of -86.07%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 21.52%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Inhibrx Biosciences, Inc..

Inhibrx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.587%.

Inhibrx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Inhibrx Biosciences, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Inhibrx Biosciences, Inc.'s net income of -$35.3M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Inhibrx Biosciences, Inc.'s price-to-earnings ratio is 0.20x while Ligand Pharmaceuticals, Inc.'s PE ratio is 96.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences, Inc. is 936.51x versus 15.69x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pelthos Therapeutics, Inc. has a net margin of -2204.15% compared to Inhibrx Biosciences, Inc.'s net margin of -219.26%. Inhibrx Biosciences, Inc.'s return on equity of -151.49% beat Pelthos Therapeutics, Inc.'s return on equity of -241.95%.

Inhibrx Biosciences, Inc. has a consensus price target of $12.00, signalling downside risk potential of -86.07%. On the other hand Pelthos Therapeutics, Inc. has an analysts' consensus of $59.80 which suggests that it could grow by 133.32%. Given that Pelthos Therapeutics, Inc. has higher upside potential than Inhibrx Biosciences, Inc., analysts believe Pelthos Therapeutics, Inc. is more attractive than Inhibrx Biosciences, Inc..

Inhibrx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pelthos Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Inhibrx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pelthos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences, Inc. pays -- of its earnings as a dividend. Pelthos Therapeutics, Inc. pays out -- of its earnings as a dividend.

Inhibrx Biosciences, Inc. quarterly revenues are --, which are smaller than Pelthos Therapeutics, Inc. quarterly revenues of $7.4M. Inhibrx Biosciences, Inc.'s net income of -$35.3M is lower than Pelthos Therapeutics, Inc.'s net income of -$16.2M. Notably, Inhibrx Biosciences, Inc.'s price-to-earnings ratio is 0.20x while Pelthos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences, Inc. is 936.51x versus 8.74x for Pelthos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.